Ipsen Manufacturing
Ipsen is a biotechnological group aiming to become a leader in specialty healthcare solutions for debilitating diseases. Its strategy is supported by three franchises, neurology, endocrinology and urology-oncology.
Ipsen has a growing portfolio in prostate cancer, bladder cancer or neuro-endocrine tumours and a presence in primary care.
The group has more than 4,500 employees spread across R&D and manufacturing sites located in China, France, Ireland, the UK and the US.
Financial Data
-
31st Dec 16 Source: CRO
- €103 million turnover
-
€85.7 million
profit - 111 employees
-
31st Dec 15 Source: CRO
- €89.4 million turnover
-
€74.3 million
profit - 99 employees
- 4 more years available »
Ranking
By Turnover
(€103 million)- 457th in Top Companies
- 49th in Health
- 48th in Pharma
- 68th in Manufacturing
By Employees
(111)- 686th in Top Companies
- 81st in Health
- 63rd in Pharma
- 105th in Manufacturing
- 111
- €103 million
Employees
- James Byrne General Manager
Latest News
- Nov 17 Facebook’s new PR disaster shows it has a lot of growing up to do
- Nov 16 Market chaos over Brexit lessens but investors remain nervous
- Nov 16 European markets down as Brexit turmoil continues to take toll
- Nov 16 Post-bailout inspectors warn of risks to growing economy
- Nov 16 Vivendi shares surge as music business drives growth